Owners of patent portfolios in the pharmaceutical space will be aware of how patent infringement claims and attacks on patent validity often interact.
As patent infringement litigation heads towards trial, patentees might expect that they will receive an interim injunction from the court in order to preserve the existing market position, at least temporarily. This is not always the case, however, as Alasdair Poore discusses in his analysis of the Neurim litigation.
Read more here.